---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-263316"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2021-09-01T23:59:59+00:00"
generated_at: "2026-06-29T06:34:43.709365+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Dermata appoints Kyri Van Hoose as CFO; Thomas Insley resigns, becomes consultant

## Summary
- Kyri Van Hoose appointed SVP, CFO effective Sept 1, 2021; previously CFO at TEGA Therapeutics.
- Thomas Insley resigned as CFO but remains as financial consultant via consulting agreement.
- Van Hoose granted stock options for 75,000 shares at $5.39, vesting over 48 months from Oct 1, 2021.
- Insley served as CFO for 6 years; transition supports continued development of DMT310 and DMT410.

## SEC filing metadata
- accession: 0001193125-21-263316
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2021-09-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000119312521263316/0001193125-21-263316-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000119312521263316/d227068d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-263316
- JSON: https://secwatch.observer/filing/0001193125-21-263316.json
- Plain text: https://secwatch.observer/filing/0001193125-21-263316.txt

## Key facts
- Executive change
  Kyri Van Hoose was appointed as Senior Vice President, Chief Financial Officer at Dermata Therapeutics, Inc..
  - Action: appointed
  - Role: Senior Vice President, Chief Financial Officer
  source text: appointed Kyri Van Hoose as Senior Vice President, Chief Financial Officer, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1853816/000119312521263316/0001193125-21-263316-index.htm
- Executive change
  Thomas Insley resigned as Chief Financial Officer at Dermata Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On September 1, 2021, Thomas Insley resigned as Chief Financial Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1853816/000119312521263316/0001193125-21-263316-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.